Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 87 Enz. Inhib. hit(s) with all data for entry = 2132
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355665(1-(2-{(1R,3S,5S)-3-[(1R,2S)-2-(2-Chloro-phenyl)-cy...)
Affinity DataIC50:  22nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355637((1R,3S,5R)-2-[2-(3-Acetyl-indazol-1- yl)-acetyl]-2...)
Affinity DataIC50:  29nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355700((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...)
Affinity DataIC50:  30nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355683(1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Fluoro-2-phenyl- cy...)
Affinity DataIC50:  30nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355654(5-Ethyl-1-{2-oxo-2-[(1R,3S,5R)-3- ((1R,2S)-2-pheny...)
Affinity DataIC50:  31nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355681((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...)
Affinity DataIC50:  32nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355702(1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...)
Affinity DataIC50:  35nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355709(1-(2-{(1R,3S,5R)-3-[2-(2,4- Difluoro-phenyl)- cycl...)
Affinity DataIC50:  36nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355685(1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...)
Affinity DataIC50:  36nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355694((2S,4R)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4-fl...)
Affinity DataIC50:  37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355703(1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...)
Affinity DataIC50:  37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355666((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1...)
Affinity DataIC50:  37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355693(1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2-Chloro-phenyl)-cy...)
Affinity DataIC50:  39nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355645((2S,3S,4S)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4...)
Affinity DataIC50:  40nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355701((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...)
Affinity DataIC50:  44nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355653(1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  44nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355708(1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...)
Affinity DataIC50:  45nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355722(3-Acetyl-1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2-fluoro-p...)
Affinity DataIC50:  46nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355674(1-{2-[(1R,3S,5R)-3-((1R,2R)-2-fluoro-2-phenyl-cycl...)
Affinity DataIC50:  48nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355661(5-Fluoro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro-2-p...)
Affinity DataIC50:  60nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355647(1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  60nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355698((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...)
Affinity DataIC50:  64nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355644(1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  65nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355679((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...)
Affinity DataIC50:  66nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355706(1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)- 2-(2-fluoro-phe...)
Affinity DataIC50:  90nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355640((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...)
Affinity DataIC50:  106nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355691((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...)
Affinity DataIC50:  109nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355660(5,6-Difluoro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro...)
Affinity DataIC50:  110nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355669((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...)
Affinity DataIC50:  112nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355713(1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...)
Affinity DataIC50:  114nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355650(5-Methyl-1-{2-oxo-2-[(1R,3S,5R)-3- ((1R,2S)-2-phen...)
Affinity DataIC50:  115nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355652(1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  117nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355649(1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  118nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355664((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1...)
Affinity DataIC50:  119nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355662(5-Chloro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro-2-p...)
Affinity DataIC50:  119nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355643((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...)
Affinity DataIC50:  123nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355705(1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Fluoro-phenyl)- ...)
Affinity DataIC50:  125nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355697((1R,2S,5S)-3-[2-(3-Acetyl-indazol- 1-yl)-acetyl]-3...)
Affinity DataIC50:  131nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355675(1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)- 2-(2-fluoro-phe...)
Affinity DataIC50:  142nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355638((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[4,3-c]pyridin-...)
Affinity DataIC50:  147nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355648(1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...)
Affinity DataIC50:  172nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355663((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-b]pyridin-1...)
Affinity DataIC50:  172nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355678(1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Fluoro-2-phenyl- cy...)
Affinity DataIC50:  214nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355689((1R,3S,5R)-2-[2-(3-Acetyl-pyrazolo[3,4-b]pyridin-1...)
Affinity DataIC50:  225nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355646((1R,3S,5R)-2-[2-(3-Acetyl-5,6- dimethoxy-indazol-1...)
Affinity DataIC50:  226nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355717(1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...)
Affinity DataIC50:  230nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355695((2S,4R)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4-fl...)
Affinity DataIC50:  294nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355707(1-(2-{(2S,4R)-2-[(1R,2S)-2-(4- Chloro-phenyl)- cyc...)
Affinity DataIC50:  309nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355667(US9815819, 32)
Affinity DataIC50:  326nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355685(1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...)
Affinity DataIC50:  367nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 87 total ) | Next | Last >>
Jump to: